Drug Profile
RO 0730699
Alternative Names: RO-0730699Latest Information Update: 01 Apr 2008
Price :
$50
*
At a glance
- Originator Roche
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 19 Mar 2007 Roche completed multicentre, phase II clinical studies in Type-2 diabetes
- 22 May 2006 Phase-II clinical trials in Type-2 diabetes mellitus in World (PO)